Post-marketing safety profile of avocado-soybean unsaponifiables;Profil d'effets indésirables des insaponifiables d'avocat et de soja

Presse Medicale

Volumn 39, Issue 10, 2010, Pages

  Olivier, Pascale ^a,b   Montastruc, Jean Louis ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PIASCLEDINE; ALPHA TOCOPHEROL; DRUG COMBINATION; PHYTOSTEROL; PLANT EXTRACT;

AGED; ARTICLE; BLOOD CLOTTING DISORDER; COLITIS; DIARRHEA; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECZEMA; FEMALE; FRANCE; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; POSTMARKETING SURVEILLANCE; THROMBOCYTE DISORDER; UNSPECIFIED SIDE EFFECT; URTICARIA; ADULT; BLOOD COAGULATION DISORDERS; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG ERUPTIONS; DRUG-INDUCED LIVER INJURY; FACTUAL DATABASE; GASTROINTESTINAL DISEASES; HOSPITALIZATION; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PERSEA; PHYTOTHERAPY; RHEUMATIC DISEASES; SAFETY; SOYBEAN; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION DISORDERS; DATABASES, FACTUAL; DRUG COMBINATIONS; DRUG ERUPTIONS; DRUG-INDUCED LIVER INJURY; FEMALE; FRANCE; GASTROINTESTINAL DISEASES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PERSEA; PHYTOSTEROLS; PHYTOTHERAPY; PLANT EXTRACTS; PRODUCT SURVEILLANCE, POSTMARKETING; RHEUMATIC DISEASES; SAFETY; SOYBEANS; VITAMIN E;

EID: 77957331313     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2010.01.013     Document Type: Article

References (24)

1. Dictionnaire e-Vidal®, consulté le 6 avril 2009.
2. Anonyme. Assurance maladie Caisse Nationale ; Point d'information mensuel 1er août 2008. Médicaments remboursés: analyse de la consommation en 2007. p. 8. http://www. ameli. fr/fileadmin/user_upload/documents/medicam_2008. pdf.
3. Anonyme. Liste des 50 produits prescrits et rembourses (en quantité) en 2004. Source CNAMTS.
4. Bégaud B., Evreux J.C., Jouglard J., Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée. Thérapie 1985, 40:115-118.
5. Aronson J.K., Ferner R.E. Clarification of terminology in drug safety. Drug Saf 2005, 28:851-870.
6. ®. Gastroenterol Clin Biol 2004, 28:412-413.
7. Appelboom T, Schuermans J, Verbruggen G, Henrotin Y, Reginster JY. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. Scand J Rheumatol 2001;30:242-7.
8. Lequesne M., Maheu E., Cadet C., Dreiser R.L. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care Res 2002, 47:50-58.
9. Blotman F., Maheu E., Wulwik A., Caspard H., Lopez A. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum (Engl Ed) 1997, 64:825-834.
10. Maheu E., Mazières B., Valat J.P., Loyau J.P., Le Loet X., Bourgeois P. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter trial with a six-month treatment period and two-month follow-up demonstrating a persistent effect. Arthritis Rheum 1998, 41:81-91.
11. Christensen R., Bartels E.M., Astrup A., Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008, 16:399-408.
12. Little C.V., Pearsons T., Logan S. Herbal therapy for treating osteoarthritis. Cochrane Database of Syst Rev 2001, 1:CD002947.
13. Amaye L.G., Chee W.S.S. Osteoarthritis nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. Arthritis Res Ther 2006, 8:R127.
14. Montastruc J.L., Sommet A., Lacroix I., Olivier P., Durrieu G., Damase-Michel C., et al. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine 2006, 73(6):629-632.
15. Tysk C. Drug-induced enterocolitis: important differential diagnosis in the investigation of diarrhea and intestinal hemorrhage. Lakartidningen 2000, 24(97):2606-2610. [abstract].
16. Beaugerie L., Luboinski J., Brousse N., Cosnes J., Chatelet F.P., Gendre J.P., et al. Drug induced lymphocytic colitis. Gut 1994, 35:426-428.
17. Pierrugues R., Saingra B. Colite lymphocytaire et Cyclo 3 fort: 4 nouvelles observations. Gastroenterol Clin Biol 1996, 20:916-917.
18. ®. Gastroenterol Clin Biol 1992, 16:373.
19. ® associée à une colite lymphocytaire. Gastroenterol Clin Biol 1999, 23:1101.
20. Maheu E. Les insaponifiables d'avocat-soja dans le traitement de la gonarthrose et de la coxarthrose. Synoviale 1992, 9:31-38.
21. Ernst E. Avocado-soybean unsaponifiables (ASU) for osteoarthritis - a systematic review. Clin Rheumatol 2003, 22:285-288.
22. Soeken K.L. Selected CAM therapies for arthritis-related pain: the evidence from systematic reviews. Clin J Pain 2004, 20:13-18.
23. Avis de la Commission de la Transparence du 15/02/2006; http://www. has-sante.fr/portail/upload/docs/application/pdf/ct032522.pdf.
24. Avis de la Commission de la Transparence du 26/11/2008; http://www.has-sante.fr/portail/upload/docs/application/pdf/2008-12/piascledine_-_ct-5536.pdf.